Clinical Trial: Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272434) titled 'Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)' on Nov. 14.

Brief Summary: This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults>= 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.

Study Start Date: Oct. 22

Study Type: INTERVENTIONAL

Condition: Respiratory Syncytial Virus (RSV)

Intervention: BIOLOGICAL: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

0.5 mL ...